Navigation Links
Raptor Pharmaceuticals Provides Update on Targeting Platforms
Date:11/6/2008

ns and Methods for Modulating Blood-Brain Barrier Transport." Allowed claims concern methods for identifying molecules that cross from blood to brain through a specific receptor-dependent process. The patent is designed to provide some protection in Japan to Raptor's NeuroTrans(TM) platform currently in development to potentially transport therapeutics from the blood to the brain.

Dr. Christopher M. Starr, President and CEO of Raptor, commented, "The progress we've made with our RAP-based development programs adds another layer of depth to our development pipeline. We believe that the proposed research with Brigham and Women's Hospital is likely to add significant value to our RAP-based approach and the Japanese patent will aid in protecting our emerging NeuroTrans(TM) platform. Over the last year we have initiated three mid-stage clinical studies with in-licensed compounds while we advanced our RAP-based preclinical drug candidates and drug-targeting platforms. We have what we believe is a promising suite of clinical-stage product candidates and preclinical drug-targeting platforms that is designed to address a wide and growing range of unmet medical needs."

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company focused on improving drug targeting to expand the reach and benefit of existing therapeutics into underserved patient populations. The Company is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit '/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
3. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
6. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
7. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Alimera Sciences To Release Second Quarter 2014 Results 2
... in LDL-C when Treated with 300 mg/week ISIS 301012 ... for 13 Weeks, - Study Presented in Poster Session Today at DALM Symposium in New York ... City, - Isis Will Host a Conference ... at http://www.isispharm.com , ...
... today,announced that the company has been awarded a ... and Technology (NIST) to develop a Sensor,System on ... markers in,a single assay. Successful development of ... of multifactorial conditions such as autoimmune disease and,allergy, ...
Cached Medicine Technology:Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 6Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 2Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 3Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 4
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July ... don,t view their kids as unhealthy or recognize the health ... study. The children of the families surveyed for the ... Children,s Hospital in Providence, R.I. "A third categorized their ... Dr. Kyung Rhee, now an assistant professor of pediatrics at ...
(Date:7/24/2014)... of overweight and obese preschoolers works better when treatment ... the child is targeted, according to research published this ... University at Buffalo and Women and Children,s Hospital of ... obese and had one parent who participated in the ... body mass index (BMI) measurements, calculated based on height ...
(Date:7/24/2014)... When a foreign material like a medical device or ... body always responds. According to Northwestern University,s Guillermo Ameer, ... and affect the device,s function. , "You will always ... professor of biomedical engineering in Northwestern,s McCormick School of ... the Feinberg School of Medicine. "A problem with commonly ...
(Date:7/24/2014)... 2014 Horizon BCBSNJ’s second annual “Back ... family a rent-free week in a beautiful Lavallette shore ... Don’t miss your chance to win a week’s vacation ... all New Jersey residents, 25 or older.* Residents can ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at the ...
(Date:7/24/2014)... Members of the Iowa State Board of Health ... of Sales at OutcomesMTM, as their Chairperson. Wolnerman said he ... and that his peers chose to keep him in this ... I can for the citizens of Iowa,” Wolnerman said. “As ... a special insight to concerns and issues related to the ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Antioxidant biomaterial promotes healing 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... celebrating his one Year Anniversary as a Non-Smoker 60 Pounds Lighter. What ... quit smoking or lose 60 pounds but to do both within one year ... was able to turn his life around and improve his quality of life; ... , ...
... voice preference on two California reorganization plans , ... members began casting ballots this week in an advisory vote ... register their preferences on whether they want to be part ... a new statewide local representing a broader classification of healthcare ...
... County Health Director, Dr. Bob England Encourage all Families to ... One Middle School , , ... that Arizona has its first lab-confirmed case of influenza in ... Public Health, the Arizona Department of Health Services, the Arizona ...
... announced today the Company will hold an,investor conference call to discuss current business conditions ... is,(866) 901-2585. The international call in number is (404) 835-7099. , , ... & ... ctrego@minrad.com , ...
... Consulting Inc.,announces the addition of two new areas of ... engineering and technology,services. The company is also launching its ... The company has realigned its services into ... sustainability. , "We ...
... useful, studies find , , WEDNESDAY, Nov. 19 (HealthDay News) -- ... diabetes was no better at predicting a person,s risk for ... , The news is both encouraging and discouraging. , "The ... risk," said Dr. James Meigs, lead author of one of ...
Cached Medicine News:Health News:Former Smoker Celebrates One Year Anniversary of Being a Non-Smoker 60 Pounds Lighter 2Health News:Former Smoker Celebrates One Year Anniversary of Being a Non-Smoker 60 Pounds Lighter 3Health News:Advisory Vote Begins on California Long-Term Care Local 2Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 2Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 3Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 4Health News:Environmental and Technology Firm Integral Consulting Inc. Expands Services, Launches New Website 2Health News:Genetic Testing No Real Help in Predicting Type 2 Diabetes 2Health News:Genetic Testing No Real Help in Predicting Type 2 Diabetes 3
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein G - 50 OD...
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: